Epstein-Barr Virus and Cytomegalovirus Coinfection in Egyptian COVID-19 Patients.

The article focuses on three medical studies conducted in Egypt related to COVID-19 and Helicobacter pylori (H. pylori) infection. The first study analyzed 227 COVID-19 patients with moderate to severe symptoms, finding that elevated interleukin-6 (IL-6) levels were significantly associated with prolonged hospital stay, disease severity, and higher mortality. The second study examined coinfection with Epstein-Barr virus (EBV) and cytomegalovirus (CMV) in 110 COVID-19 patients with elevated liver enzymes, reporting a 4.5% prevalence for each virus; coinfection was linked to longer hospital stays but did not affect disease severity or clinical outcomes. The third study compared the efficacy of potassium-competitive acid blockers (P-CABs) versus proton pump inhibitors (PPIs) in eradicating H. pylori infection among treatment-naive and experienced patients, finding no significant difference between the two therapies in eradication rates.